Table 3.

Univariate models for overall survival

Overall survival	Total cohort		HPV-positive OPSCC		HPV-negative OPSCC
	Hazard ratio (95 % CI)	p value	Hazard ratio (95 % CI)	p value	Hazard ratio (95 % CI)	p value
Gender (male vs. female)	0.85 (0.59–1.23)	0.387	0.34 (0.04–2.68)	0.305	0.86 (0.59–1.26)	0.434
Age (>60 vs. younger)	1.08 (0.78–1.51)	0.644	3.97 (1.02–15.4)	0.046	0.93 (0.66–1.31)	0.670
Tumor size (T3–4 vs. T1–2)	2.10 (1.45–3.00)	<0.001	3.19 (0.82–12.4)	0.093	1.90 (1.32–2.74)	<0.001
Nodal stage (N+ vs. N0)	1.82 (1.26–2.62)	<0.001	1.14 (0.14–9.00)	0.902	2.55 (1.73–3.77)	<0.001
Smoking (current/quit vs. never ever)	0.78 (0.56–1.09)	0.148	0.77 (0.53–1.11)	0.159	0.79 (0.56–1.11)	0.176
Alcohol use (current/quit vs. never ever)	1.00 (0.71–1.43)	0.97	1.53 (0.44–5.29)	0.501	0.77 (0.53–1.11)	0.768
Number of CD3+ cells (>150 vs. 0–149)	0.36 (0.21–0.61)	<0.001	0.29 (0.09–0.95)	0.042	0.61 (0.37–1.03)	0.065
Number of CD4+ cells (>100 vs. 0–99)	0.66 (0.43–1.00)	0.051	0.58 (0.16–2.05)	0.393	0.84 (0.54–1.32)	0.456
Number of CD8+ cells (>100 vs. 0–99)	0.37 (0.22–0.62)	<0.001	0.31 (0.08–1.24)	0.100	0.57 (0.32–1.01)	0.054
SERPINB1 (>50 % vs. 0–49 %)	1.60 (1.11–2.31)	0.012	4.58 (1.22–17.1)	0.024	1.37 (0.93–2.00)	0.110
SERPINB4 (H-score) (>150 vs. 0–149)	1.12 (0.79–1.58)	0.527	1.92 (0.56–6.63)	0.304	1.05 (0.73–1.50)	0.812
SERPINB9 (>10 % vs. 0–9 %)	0.84 (0.47–1.50)	0.563	0.05 (0.00–7397)	0.637	0.75 (0.42–1.34)	0.330
HPV (positive vs. negative)	0.28 (0.15–0.54)	<0.001	–	–	–	–
Treatment (CCRT vs. surgery)	1.41 (0.98–2.01)	0.062	34.67 (0.11–11372)	0.230	1.38 (0.96–1.99)	0.081

Significant values are shown in bold

HPV Human papillomavirus, OPSCC oropharyngeal squamous cell carcinoma, CI confidence interval, CCRT radiotherapy with or without adjuvant chemotherapy